Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2018	Oct. 31, 2017	[2]
Cash flows from operating activities:
Net loss	$ (94,686)	$ (86,804)	[1]
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation	53,899	35,292
Depreciation, amortization and accretion	5,824	5,111
Amortization of debt discount and issuance costs	10,315	0
Amortization of deferred commissions	14,963	10,911
Deferred income taxes	(2,269)	(960)
Non-cash charitable contributions	1,008	708
Other	153	997
Changes in operating assets and liabilities, net of business combination:
Accounts receivable	(17,539)	(12,742)
Deferred commissions	(25,907)	(16,230)
Prepaid expenses and other assets	(4,238)	(2,353)
Accounts payable	1,354	6,255
Accrued compensation	7,973	5,931
Accrued expenses and other liabilities	8,182	(1,545)
Deferred revenue	46,036	30,034
Net cash provided by (used in) operating activities	5,068	(25,395)
Cash flows from investing activities:
Capitalization of internal-use software costs	(2,329)	(4,072)
Purchases of property and equipment	(14,253)	(5,570)
Purchases of securities available for sale	(478,138)	(95,344)
Proceeds from maturities of securities available for sale	219,650	21,985
Proceeds from sales of securities available for sale	12,470	1,538
Payments for business acquisition, net of cash acquired	(15,616)	0
Net cash used in investing activities	(278,216)	(81,463)
Cash flows from financing activities:
Proceeds from initial public offering, net of underwriters' discounts and commissions	0	199,948
Proceeds from issuance of convertible senior notes, net of issuance costs	334,980	0
Purchase of convertible senior notes hedge	(80,040)	0
Proceeds from issuance of warrants related to convertible notes	52,440	0
Payments of deferred offering costs	0	(4,038)
Proceeds from stock option exercises, net of repurchases	28,524	25,800
Proceeds from shares issued in connection with employee stock purchase plan	6,654	0
Other	(206)	(343)
Net cash provided by financing activities	342,352	221,367
Effects of changes in foreign currency exchange rates on cash and cash equivalents	(990)	53
Net increase in cash, cash equivalents and restricted cash	68,214	114,562
Cash, cash equivalents and restricted cash at beginning of period	136,233	23,282
Cash, cash equivalents and restricted cash at end of period	204,447	137,844
Non-cash investing and financing activities:
Vesting of early exercised common stock options	629	986
Issuance of common stock in connection with warrant exercises	0	272
Common stock issued as charitable contribution	1,008	708
Property and equipment acquired through tenant improvement allowance	22,237	0
Property and equipment and other accrued but not yet paid	1,431	710
Issuance of common stock in connection with business combination	0	2,160
Conversion of redeemable convertible preferred stock to common stock	0	228,362
Reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets to the amounts shown in the statements of cash flows above:
Total cash, cash equivalents and restricted cash	$ 136,233	$ 23,282

[1] See Note 2 for a summary of adjustments.

[2] See Note 2 for a summary of adjustments.